T1	Pharmacological_substance 10 20	Olanzapine
N1000 	Reference T1 MeSH:C076029	Olanzapine
T2	Disorder 29 48	hyperglycaemic coma
N1 	Reference T2 UMLS:C1263960	hyperglycaemic coma
T3	Disorder 53 83	neuroleptic malignant syndrome
N2 	Reference T3 UMLS:C0027849	neuroleptic malignant syndrome
T4	Pharmacological_substance 158 182	antipsychotic medication
N1001 	Reference T4 MeSH:D014150	antipsychotic medication
N1002 	Reference T4 MeSH:D014150	antipsychotic medication
T5	Pharmacological_substance 197 229	second-generation antipsychotics
T6	Disorder 242 263	metabolic disturbance
T7	Disorder 421 451	neuroleptic malignant syndrome
N3 	Reference T7 UMLS:C0027849	neuroleptic malignant syndrome
T8	Disorder 453 456	NMS
N4 	Reference T8 UMLS:C0270699	NMS
N5 	Reference T8 UMLS:C0027849	NMS
T9	Disorder 514 549	new onset type II diabetes mellitus
N6 	Reference T9 UMLS:C0011849	new onset type II diabetes mellitus
T10	Disorder 555 587	hyperosmolar hyperglycaemic coma
T11	Disorder 592 611	acute renal failure
N7 	Reference T11 UMLS:C0022660	acute renal failure
N8 	Reference T11 UMLS:C3854173	acute renal failure
T12	Disorder 655 668	manic episode
N9 	Reference T12 UMLS:C0349208	manic episode
T13	Disorder 793 806	diabetic coma
N10 	Reference T13 UMLS:C1263960	diabetic coma
T14	Pharmacological_substance 812 826	antipsychotics
N1003 	Reference T14 MeSH:D014150	antipsychotics
T15	Disorder 861 875	hyperglycaemia
N11 	Reference T15 UMLS:C0020456	hyperglycaemia
T16	Disorder 880 892	hyperthermia
N12 	Reference T16 UMLS:C0015967	hyperthermia
T18	Pharmacological_substance 231 235	SGAs
T19	Subject 481 499	35-year old female
T20	Pharmacological_substance 639 642	SGA
T23	Disorder 719 722	NMS
N13 	Reference T23 UMLS:C0270699	NMS
N14 	Reference T23 UMLS:C0027849	NMS
T25	Speculation_cue 734 760	raises important questions
